THURSDAY, Nov. 21, 2024 (HealthDay News) -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the ...

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...